日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Daprodustat and Heart Failure in CKD

达普司他与慢性肾脏病患者的心力衰竭

Cunningham, Jonathan W; Claggett, Brian L; Lopes, Renato D; McMurray, John J V; Perkovic, Vlado; Carroll, Kevin; Hiemstra, Thomas; Khavandi, Kaivan; Lukas, Mary Ann; Ranganathan, Prerna; Shannon, Jennifer; van Adelsberg, Janet; Singh, Ajay K; Solomon, Scott D

Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis

一项随机 III 期试验中,沙利鲁单抗单药治疗与阿达木单抗单药治疗类风湿性关节炎患者的患者报告结局

Strand, Vibeke; Gossec, Laure; Proudfoot, Clare W J; Chen, Chieh-I; Reaney, Matthew; Guillonneau, Sophie; Kimura, Toshio; van Adelsberg, Janet; Lin, Yong; Mangan, Erin K; van Hoogstraten, Hubert; Burmester, Gerd R

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes

沙利鲁单抗治疗对甲氨蝶呤疗效不佳的类风湿性关节炎患者两年:安全性、有效性和影像学结果

Genovese, Mark C; van Adelsberg, Janet; Fan, Chunpeng; Graham, Neil M H; van Hoogstraten, Hubert; Parrino, Janie; Mangan, Erin K; Spindler, Alberto; Huizinga, Tom W J; van der Heijde, Désirée

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

沙利鲁单抗单药治疗与阿达木单抗单药治疗活动性类风湿关节炎患者的疗效和安全性比较(MONARCH):一项随机、双盲、平行组 III 期试验

Burmester, Gerd R; Lin, Yong; Patel, Rahul; van Adelsberg, Janet; Mangan, Erin K; Graham, Neil M H; van Hoogstraten, Hubert; Bauer, Deborah; Ignacio Vargas, Juan; Lee, Eun Bong

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

对于活动性类风湿关节炎且对肿瘤坏死因子抑制剂反应不足或不耐受的患者,可采用沙利鲁单抗和非生物疾病修饰抗风湿药物进行治疗。

Fleischmann, Roy; van Adelsberg, Janet; Lin, Yong; Castelar-Pinheiro, Geraldo da Rocha; Brzezicki, Jan; Hrycaj, Pawel; Graham, Neil M H; van Hoogstraten, Hubert; Bauer, Deborah; Burmester, Gerd R

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.

Sarilumab 联合甲氨蝶呤可抑制类风湿性关节炎患者(对甲氨蝶呤反应不足)体内骨吸收和滑膜损伤的循环生物标志物:一项 MOBILITY 生物标志物研究

Boyapati Anita, Msihid Jérôme, Fiore Stefano, van Adelsberg Janet, Graham Neil M H, Hamilton Jennifer D

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

Sarilumab 是一种针对 IL-6Rα 的全人源单克隆抗体,用于治疗对甲氨蝶呤反应不足的类风湿性关节炎患者:随机 SARIL-RA-MOBILITY A 部分试验的疗效和安全性结果

Huizinga, Tom W J; Fleischmann, Roy M; Jasson, Martine; Radin, Allen R; van Adelsberg, Janet; Fiore, Stefano; Huang, Xiaohong; Yancopoulos, George D; Stahl, Neil; Genovese, Mark C